Results 301 to 310 of about 1,938,552 (387)
Intestinal Atresia in PPP1R12A‐Related Urogenital and Brain Malformation Syndrome
ABSTRACT PPP1R12A‐related urogenital and brain malformation syndrome (UBMS) is a newly described disorder characterized by congenital anomalies primarily involving the urogenital system and the brain. We describe a preterm female neonate with multiple congenital anomalies, including type IIIb jejunal atresia, incomplete intestinal rotation, imperforate
Adriana Gomes+4 more
wiley +1 more source
Adherence to guidelines on quality neonatal resuscitation practices among healthcare professionals in Ghana: an observational study. [PDF]
Salia SM+3 more
europepmc +1 more source
ABSTRACT Apert syndrome is a recognizable craniofacial condition characterized by craniosynostosis, hypertelorism, exorbitism, midface hypoplasia, and complex symmetrical bony and cutaneous ‘mitten’ syndactyly of all four limbs. Around 98% of affected patients have one of two heterozygous missense variants in the FGFR2 gene, encoding either p ...
Ramy Saad+8 more
wiley +1 more source
Association between total oxytocin dose and maternal and neonatal morbidity during labour induction: a retrospective study. [PDF]
Payrastre C+5 more
europepmc +1 more source
Long-term effects of neonatal pain.
S. Walker
semanticscholar +1 more source
SPONTANEOUS ACTIVITY OF NEONATALLY ESTROGENIZED FEMALE RATS
Seiichiro Kawashima, Akira Shinoda
openalex +2 more sources
ABSTRACT Turner Syndrome (TS) is a sex chromosomal disorder associated with karyotype heterogeneity. Although TS can be associated with severe prenatal findings, most often linked to the 45, X karyotype, the majority of TS fetuses have no overt phenotype, resulting in delayed diagnosis and management.
Ivonne Bedei+10 more
wiley +1 more source
Gestational reactive hypoglycaemia and adverse pregnancy outcomes: a systematic review and meta-analysis. [PDF]
Mahindra MP+7 more
europepmc +1 more source
ABSTRACT Rare diseases impact approximately 1 in 10 people worldwide, and yet, less than 5% of all rare diseases currently have an approved treatment option available. This is due to many challenges unique to rare diseases, including small, diverse patient populations, the cost of drug development that is not proportionate to the number of patients who
Caleb P. Bupp+7 more
wiley +1 more source